OlympiA Trial (NSABP B-55): Olaparib as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

March 16 2022

The updated results of the OlympiA Trial (NSABP B-55) were presented today at a virtual plenary session of the European Society of Medical Oncology (ESMO) by the Global Study Chair, Andrew Tutt, Professor of Oncology at The Institute of Cancer Research, London, and King’s College London.

These results showed that olaparib significantly improved overall survival (OS) in patients with HER2-negative early breast cancer and germline BRCA mutations.

Click here to read the full Press Release.

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.